secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-04-20T23:59:59+00:00
Accession:  0000950170-23-013583
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics announces commercial leadership changes: Poyhonen, Mathews depart; Grillot appointed VP
--------------------------------------------------------------------------------

- John Poyhonen ceases as President and Chief Commercial Officer effective April 30, 2023.
- Michael Mathews ceases as SVP Commercial, Acute Care effective April 30, 2023.
- Jason Grillot appointed VP Sales and Marketing, Acute Care effective April 24, 2023.
- Grillot granted 350,000 stock options with 4-year vesting as material inducement.
- CEO Craig Collard will oversee commercial organization after departures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017023013583/0000950170-23-013583-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017023013583/hrtx-20230418.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-013583

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer